Novo Nordisk A/S AGM Statement

BAGSVAERD, Denmark, March 9 /PRNewswire/ -- Annual General Meeting at Novo Nordisk A/S .

At the Annual General Meeting of Novo Nordisk A/S today, the shareholders made the following resolutions:

* Adoption of the audited Annual Report 2004, including approval of the remuneration of the Board of Directors. * Resolution to distribute the profit according to the adopted Annual Report 2004. The dividend will be DKK 4.80 per share of DKK 2, an increase of 9% compared with 2003. * Board members elected by the Annual General Meeting: Re-election of Mads Ovlisen, Sten Scheibye, Kurt Briner, Niels Jacobsen, Kurt Anker Nielsen and Jorgen Wedel and election of Goran A Ando and Henrik Gurtler. * Re-election of the auditor, PricewaterhouseCoopers. * Authorisation to the Board of Directors, until the next Annual General Meeting, to allow Novo Nordisk A/S to acquire own shares of up to 10% of the share capital and at the price quoted on the date of purchase with a deviation of up to 10%, cf Article 48 of the Danish Companies Act. The Board of Directors Accordingly the Board of Directors of Novo Nordisk A/S comprises: * Mads Ovlisen * Sten Scheibye * Goran A Ando * Kurt Briner * Henrik Gurtler * Johnny Henriksen (employee representative) * Niels Jacobsen * Anne Marie Kverneland (employee representative) * Kurt Anker Nielsen * Stig Strobaek (employee representative) * Jorgen Wedel

For information on the board members, please refer to http://www.novonordisk.com/.

At a board meeting immediately after the Annual General Meeting, the Board of Directors constituted itself with Mads Ovlisen as chairman and Sten Scheibye as vice chairman.

The Board of Directors elected Kurt Anker Nielsen, Niels Jacobsen and Jorgen Wedel as members of the Audit Committee with Kurt Anker Nielsen as chairman. Kurt Anker Nielsen and Niels Jacobsen were designated by the Board of Directors as Audit Committee Financial Experts.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 20,250 full-time employees in 78 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit http://www.novonordisk.com/.

For further information please contact: Media: Investors: Outside North America: Outside North America: Mike Rulis Mogens Thorsager Jensen Tel (direct): (+45) 4442 3573 Tel (direct): (+45) 4442 7945 Palle Holm Olesen Tel (direct): (+45) 4442 6175 In North America: In North America: Susan T. Jackson Christian Kanstrup Tel (direct): (+1) 609 919 7776 Tel (direct): (+1) 609 919 7937 Stock Exchange Announcement No 13 /2005